Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39011
Title: | Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes: A prospective cohort study | Authors: | Miljoen, Hielko BEKHUIS, Youri Roeykens, Johan Taha, Karim Frankinouille, Rudi MICHIELSEN, Matthijs Van de Heyning, Caroline M. M. Cornelissen, Veronique Favere, Kasper Eens, Sander Gielen , Jan Goetschalckx, Kaatje HEIDBUCHEL, Hein CLAESSEN, Guido Covivax Study Grp |
Issue Date: | 2022 | Publisher: | WILEY | Source: | Health science reports, 5 (6) (Art N° e929) | Abstract: | Background and AimsThe goal of the present study was to systematically evaluate the effect of a booster vaccination with the BNT162b2 messenger RNA (mRNA; Pfizer-BioNTech (R)) vaccine on maximum oxygen uptake (VO2max), potential signs of (peri)myocarditis, and sports participation. MethodsRecreational athletes who were scheduled to undergo booster vaccination were evaluated with transthoracic echocardiography, serum measurements of high-sensitivity C-reactive protein(hsCRP) and high-sensitivity troponin I, and a bicycle cardiopulmonary exercise test (CPET) with serum lactate evaluation before the booster vaccine administration. Seven days postvaccination the test battery was repeated. Additionally, the subjects were asked to fill in a questionnaire on side effects and a subjective evaluation of their relative training volume and intensity as compared to the weeks before vaccination. ResultsA group of 42 analysed athletes showed a statistically significant 2.7% decrease in VO2max after vaccination (mean standard error of mean pre: 48.6 (1.4) ml/kg/min; post: 47.3 (1.4) ml/kg/min; p = 0.004). A potentially clinically relevant decrease of 8.6% or more occurred in 8 (19%) athletes. Other CPET parameters and lactate curves were comparable. We found no serological or echocardiographic evidence of (peri)myocarditis. A slight but significant increase in hsCRP was noted 1 week after vaccination. Side effects were mild and sports participation was generally unchanged or mildly decreased after vaccination. ConclusionIn our population of recreational endurance athletes, booster vaccination with the BNT162b2 mRNA vaccine resulted in a statistically significant decrease in VO2max 7 days after vaccination. The clinical impact hereof needs to be further determined. No major adverse events were observed. | Notes: | Miljoen, H (corresponding author), Univ Hosp Antwerp, Dept Cardiol, Drie Eikenstraat 655, B-2650 Edegem, Belgium. hielko.miljoen@uza.be |
Keywords: | athlete;COVID-19;SARS-CoV-2;vaccination;VO2max | Document URI: | http://hdl.handle.net/1942/39011 | e-ISSN: | 2398-8835 | DOI: | 10.1002/hsr2.929 | ISI #: | 000888078400001 | Rights: | 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Effect of BNT162b2 mRNA booster vaccination on VO2max in recreational athletes_ A prospective cohort study.pdf | Published version | 859.34 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.